[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Franca_ole Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::558784211.png) @Franca_ole Franca_ole

Franca_ole posts on X about $sgmo, $sgmos, target, $pfe the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::558784211/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::558784211/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXXX +34%
- X Months XXXXXXX +19%
- X Year XXXXXXX +256%

### Mentions: X [#](/creator/twitter::558784211/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::558784211/c:line/m:posts_active.svg)

- X Week XX +11%
- X Month XXX +40%
- X Months XXX +41%
- X Year XXX +274%

### Followers: XXX [#](/creator/twitter::558784211/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::558784211/c:line/m:followers.svg)

- X Week XXX +0.10%
- X Month XXX +4.10%
- X Months XXX +30%
- X Year XXX +66%

### CreatorRank: undefined [#](/creator/twitter::558784211/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::558784211/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  XXXX%

**Social topic influence**
[$sgmo](/topic/$sgmo) #12, [$sgmos](/topic/$sgmos) #1, [target](/topic/target) 3.13%, [$pfe](/topic/$pfe) 3.13%, [fda](/topic/fda) 3.13%, [$snti](/topic/$snti) 3.13%, [status](/topic/status) 3.13%, [strong](/topic/strong) 3.13%, [sentis](/topic/sentis) 3.13%, [$4503t](/topic/$4503t) XXXX%

**Top accounts mentioned or mentioned by**
[@yusufhameed](/creator/undefined) [@researchitgg](/creator/undefined) [@saltodellupo](/creator/undefined) [@justin48413386](/creator/undefined) [@sandymacrae23](/creator/undefined) [@auditor112017](/creator/undefined) [@reg0sce](/creator/undefined) [@zinselmeyerb](/creator/undefined) [@bduclaux](/creator/undefined) [@gothamgirl_1](/creator/undefined) [@jawnzilla](/creator/undefined) [@whitecollar86](/creator/undefined)

**Top assets mentioned**
[Pfizer, Inc. (PFE)](/topic/$pfe) [Arcellx, Inc. Common Stock (ACLX)](/topic/$aclx)
### Top Social Posts
Top posts by engagements in the last XX hours

"$SGMO's latest patent application US 20250361528 A1 describes a new type of base editorgenetic engineering tools that can target and modify individual DNA bases. The inventors are developing fusion proteins that combine two functional units namely zinc finger domains (zinc finger proteins) and cytidine deaminases i.e. enzymes that convert cytosine (C) into uracil (U) resulting in a targeted CT mutation in the genome. Among other things the patent claims novel combinations of zinc fingers + deaminase specific designs that improve accuracy and efficiency and applications in which individual"  
[X Link](https://x.com/Franca_ole/status/1993984316620067150)  2025-11-27T10:04Z XXX followers, 9872 engagements


"$PFE has Hympavzi a drug for the prophylactic treatment of severe hemA and hemB. Hympavzi was approved by the FDA and EMA in 2024. The competitive product Giroctocogene Fitelparvovec was terminated by PFE on New Year's Eve 2024 and returned to $SGMO on April 2025. Fitelparvovec is based on a single-dose gene therapy with greatly reduced ABR over XX months but its long-term safety and stability are still unclear. Hympavzi shows good data for prophylactic use but has only been tested in an open-label single-arm study design. The risk profiles of the two drugs differ greatly. SGMO's gene therapy"  
[X Link](https://x.com/Franca_ole/status/1998293643564597540)  2025-12-09T07:28Z XXX followers, 2561 engagements


"$SNTI received FDA RMAT designation for SENTI-202 its off-the-shelf CAR-NK cell therapy for R/R AML following Orphan Drug status earlier this year. The designation is supported by ph1 data showing a XX% ORR XX% CR/CRh at RP2D and XXX months median duration of remission highlighting strong efficacy safety and proof-of-mechanism via selective tumor targeting with Sentis Logic Gate platform"  
[X Link](https://x.com/Franca_ole/status/1998413142439661728)  2025-12-09T15:23Z XXX followers, XXX engagements


"Astellas is looking for a Scientist Gene Regulation Technology"  
[X Link](https://x.com/Franca_ole/status/1982861791270187452)  2025-10-27T17:27Z XXX followers, 3560 engagements


"$ACLX reported a XX% ORR and XX% CR/sCR with anito-cel in pivotal ph2 iMMagine-1 for relapsed/refrac MM with deep and durable responses XX% MRD negativity and 24m PFS and OS rates of XX% and 83%. BLA submission based on October 2025 cutoff"  
[X Link](https://x.com/Franca_ole/status/1998123213973307750)  2025-12-08T20:11Z XXX followers, XXX engagements


"#Fabry $SGMO These results show that classic enzymatic measurement underestimates mutations especially in women: "Fabry Disease: Incidence of the Common Later-Onset -Galactosidase A IVS4+919GA Mutation in Taiwanese NewbornsSuperiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations""  
[X Link](https://x.com/Franca_ole/status/1999095169509912879)  2025-12-11T12:33Z XXX followers, XXX engagements